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The current definition of the post-intensive care syndrome
(PICS) includes new or worsening impairments in
physical, cognitive and/or mental health [1]. This list can
encompass a broad number of dysfunctions, syndromes or
specific diseases. In addition to muscular weakness and
post-trauma stress disorder cognitive, behavioral or
mental changes, other disorders may arise as a result of
the pathophysiological events of the acute phase of critical
illness, including physiological changes or the effects of
therapies.
We here suggest that type 2 diabetes mellitus can be
acquired during a stay in an intensive care unit (ICU-
acquired diabetes (ICU-AD)) as an additional component
of PICS. ICU-AD will increase the risks of long-term
complications and increase the burden of critical illness.
Regarding the pathogenesis of ICU-AD, persisting insulin
resistance (IR) is the most likely candidate because IR
develops rapidly during the acute phase of critical illness,
with stress hyperglycemia (SHG) representing its com-
monest expression [2–4].
In contrast to the hyperglycemia in type 2 diabetes,
which results from the combination of progressive IR
developing over years and eventually culminates in beta-
cell secretory defect, the pathogenesis of SHG involves a
much quicker and more dramatic interplay of counter-
regulatory hormones such as catecholamines, growth
hormone, cortisol and cytokine, resulting in IR and
raised hepatic glucose production (from gluconeogenesis
and glycogenolysis) [3]. The adaptive mechanisms devel-
oped to survive a stress (sympathetic activity, release of
pituitary hormones, inflammatory mediators) all result
in a resistance to anabolic signals, including insulin
[2, 3]. Teleologically, IR is considered an evolutionary
preserved mechanism designed to supply higher amounts
of glucose to insulin-independent tissues than to insulin-
dependent tissues [2]. In the presence of IR, the flow of
glucose will rise during the acute post-injury phase, trig-
gering SHG [4]. The magnitude of IR should be confirmed
by accurate assessments using isoglycemic hyperinsuline-
mic clamps. Because this technique can hardly be used in
daily clinical practice, the use of physiological modeling
including the determination of insulin sensitivity can be
very helpful and may help to improve the quality of
glycemic control.
In addition to IR, other stress-related pathophysio-
logical derangements can also contribute to the develop-
ment of ICU-AD. Among other potential mechanisms, a
partial inhibition of the incretin effect could be involved.
Such inhibition results in a lesser release of insulin in
response to enterohormones released by the duodenum,
small intestine or colon in response to oral or enteral
food ingestion than in healthy conditions. Finally, a role
of adipokines in the modulation of IR is suspected but
not convincingly supported.
By analogy with gestational diabetes, a normalization
of the sensitivity to insulin is expected after the reso-
lution of the underlying condition. Contrasting with this
belief, cohort studies have described the acquisition of
type 2 diabetes, sometimes diagnosed very late after the
resolution of the critical illness. Of note, the British
National Institute for Health and Clinical Excellence [5]
already recommended in 2011 screening for diabetes in
patients who developed SHG after an acute coronary
syndrome.
Abdelhamid et al. [6] reported recently in Critical
Care the results of a systematic review of the incidence
of diabetes of prediabetes diagnosed at least 3 months
after hospital discharge of critically ill patients. Overall,
this meta-analysis supports SHG as a risk factor for inci-
dent diabetes, when the risk of subsequent diabetes in
patients who experienced SHG was multiplied by 3.5 [6].
Even though these data are quite convincing, the
incidence of ICU-AD might be overestimated in some
studies because diabetes might be preexisting in some
patients [7, 8]. Taken together, these findings underline
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the relevance of a systematic determination of HbA1c
on admission to diagnose unknown diabetes, or to assess
the quality of glucose control in patients with known
diabetes. Alternatively, the determination of the optimal
BG target might be calculated from the value of HbA1c,
as a potential strategy during a stay in the ICU [9, 10].
Regardless of the underlying mechanism, the acquisi-
tion of type 2 diabetes suggested by the results of reverse
epidemiology techniques used by Abdelhamid et al. [6]
is a major discovery, and represents a strong incentive
for prospective studies to assess the actual incidence of
ICU-AD and related risk factors. Indeed, in spite of the
consistency of the data reported, there are several diver-
gent aspects that cannot be assessed from cohort data.
First, the definition of “new-onset” SHG varies from one
study to another. Ideally, the absence of preexisting
diabetes should be checked by the medical history and
glycated hemoglobin below 6.5%, which is not available
in most studies. Second, the severity and duration of
SHG should be reported using standard metrics and
completed by therapeutic data; that is, the amount of
insulin required to achieve the target glucose level. The
determination of a hyperglycemic index (area under the
curve above the upper limit of the target blood glucose
range) could be helpful in this regard. Likewise, the
doses of some confounding medications such as steroids
or catecholamines and the physical activity of the
patients should be recorded to tease out changes in IR
and hyperglycemia. Third, the diagnosis of diabetes
should rely on the current definition based on an oral
glucose tolerance test and/or the level of glycated
hemoglobin. Fourth, the duration of follow-up should be
considered carefully, because the timing for diagnosis of
diabetes or prediabetes differs widely between studies.
These divergent aspects should be carefully assessed
when designing prospective collections in follow-up
studies.
In conclusion, we urge for a thorough follow-up of pa-
tients after discharge from the ICU including screening
for ICU-AD. An early diagnosis of ICU-AD will allow
the early institution of appropriate treatment and the
identification of risk factors will help to prevent it. If
neglected, ICU-AD would represent a major public
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